GenomeQuest

The company exited the NGS whole-genome analysis market a few years ago and is now focused on building a business around its core IP search technology.

Robert Hoyt has joined GenomeQuest's board of directors
Hoyt is currently Eximo's chief operating officer. Prior to that, he was the general manager of Endeca Technologies which sold to Oracle in 2011.

This week, GenomeQuest launched a new Intellectual Property Management module for its software that lets customers manage their sequence IP.

Software vendors attempting to tap into the nascent clinical sequencing market are taking steps to ensure that their offerings toe the lines set by federal agencies to ensure the privacy and security of patient information.

GenomeQuest has completed an integration agreement with online information services firm Questel that allows researchers to review biological sequence patents from GenomeQuest's GQ-IP system via Questel's Orbit platform, an IP da

By Uduak Grace Thomas
Cartagenia this week released a version of its Bench Lab software that is geared toward analyzing next-generation sequence data in clinical laboratories.

By Bernadette Toner
GenomeQuest this week said that the Emory Genetics Laboratory is using its GQ-Dx software to support a suite of sequencing-based diagnostic tests it offers through its CLIA-certified facility.

Kitware has launched a beta version of Visomics, an open-source application for genomics, proteomics, transcriptomics, and metabolomics.

By Monica Heger
This story was originally published Jan. 9.
Knome has hired a new CEO as part of its strategy to expand its whole-genome sequence interpretation services into the clinic.

GenomeQuest said this week that it is awarding software and services worth more than $120,000 to six laboratories in order to help them transition Sanger-based gene tests to next-generation sequencing platforms.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.